Most people understand Alzheimer’s disease as a brain condition. Plaques. Tangles. Genetics. A neurological process that medicine has spent decades trying to reverse with drugs targeting those specific proteins.
Over forty clinical trials. Hundreds of billions of dollars in research. And in most cases, even when the drugs successfully reduced amyloid in the brain, cognition did not improve.
That pattern is a signal. And it points toward something that a specific group of researchers has been documenting since the mid-two thousands — a finding that has appeared consistently in peer-reviewed literature without ever quite making it into the clinical conversation most people at risk actually need to have.
The finding is this: the brains of people who died with Alzheimer’s disease show a consistent, measurable pattern of impaired insulin signaling and insulin receptor dysfunction in the hippocampus, the entorhinal cortex, and the frontal lobes. The same regions that deteriorate first. The same regions responsible for memory, language, and executive function.
Researchers proposed a name for this pattern: Type three diabetes.
In this video, Doctor Miranda Claire breaks down the full science behind that hypothesis — what it means biologically, why the pharmaceutical history of Alzheimer’s treatment is consistent with it, what the epidemiological evidence shows, and what it means in practical terms for any adult over fifty-five who is currently thinking about their cognitive future.
What you will learn:
— What the Type three diabetes hypothesis actually proposes, and the post-mortem brain tissue research that first documented it
— Why the blood-brain barrier paradox means that chronically high blood insulin in the body can produce insulin deficiency in the brain simultaneously
— How advanced glycation end products from chronic high blood glucose trigger the microglial activation and neuroinflammation that accelerates neuronal death
— Why the apolipoprotein E epsilon four gene variant is better understood as a metabolic vulnerability than a predetermined verdict
— What the epidemiological evidence shows about the relationship between type two diabetes, metabolic syndrome, and Alzheimer’s risk
— Why ketone bodies offer a metabolic bypass for insulin-resistant neurons — and what the brain imaging research shows about glucose versus ketone uptake in affected brain regions
— How intermittent fasting activates autophagy, the cellular cleanup mechanism responsible for clearing misfolded proteins including certain forms of amyloid and tau
— The three specific blood markers — fasting insulin, homeostatic model assessment of insulin resistance, and hemoglobin A-one-C — that tell you more about your brain’s metabolic environment than any standard cognitive screening
— What the reversibility research shows, including the pilot protocol that returned some early-stage patients to functional professional activity
— The exact questions to ask your doctor at your next appointment to move this conversation into the clinical setting where it belongs
Scientific References:
de la Monte, S. M., & Wands, J. R. (two thousand and eight). Alzheimer’s disease is type three diabetes — evidence reviewed. Journal of Diabetes Science and Technology, two, issue six, one thousand one hundred and one through one thousand one hundred and thirteen.
de la Monte, S. M. (two thousand and nine). Insulin resistance and Alzheimer’s disease. BMB Reports, forty-two, issue eight, four hundred and seventy-five through four hundred and eighty-one.
Talbot, K., Wang, H. Y., Kazi, H., et al. (two thousand and twelve). Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-one resistance, IRS-one dysregulation, and cognitive decline. Journal of Clinical Investigation, one hundred and twenty-two, issue four, one thousand five hundred and seventeen through one thousand five hundred and thirty-three.
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (two thousand and six). Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurology, five, issue one, sixty-four through seventy-four.
Henderson, S. T. (two thousand and eight). Ketone bodies as a therapeutic for Alzheimer’s disease. Neurotherapeutics, five, issue three, four hundred and seventy through four hundred and eighty.
Cunnane, S. C., Nugent, S., Roy, M., et al. (two thousand and eleven). Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition, twenty-seven, issue one, three through twenty.
Mattson, M. P., Moehl, K., Ghena, N., Schmaedick, M., & Cheng, A. (two thousand and eighteen). Intermittent metabolic switching, neuroplasticity and brain health. Nature Reviews Neuroscience, nineteen, issue two, sixty-three through eighty.
Bredesen, D. E. (two thousand and fourteen). Reversal of cognitive decline: A novel therapeutic program. Aging, six, issue nine, seven hundred and seven through seven hundred and seventeen.
source